← All trials
NCT07075146
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 5, 2025
- Primary completion
- Jun 5, 2026
- Completion date
- Aug 1, 2028
- First posted
- Jul 20, 2025
- Last posted
- Aug 24, 2025
- Enrollment
- 306
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto Mexicano del Seguro SocialLead sponsor
- Instituto Mexicano del Seguro SocialCollaborator
- Instituto Mexicano del Seguro SocialOfficial
- Instituto Mexicano del Seguro SocialSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.